Identifying novel SMYD3 interactors on the trail of cancer hallmarks

Area of Science:

• Oncology
• Molecular Biology
• Bioinformatics

Background:

• SMYD3 overexpression is observed in various human cancers, suggesting its role in carcinogenesis.
• The precise function of SMYD3 in cancer development and progression remains under investigation.
• Previous research identified BRCA2, ATM, and CHK2 as direct SMYD3 interactors using tripeptide probes.

Purpose of the Study:

• To identify novel SMYD3-interacting proteins implicated in cancer hallmarks.
• To gain insights into the potential cancer-related roles of SMYD3.
• To explore new therapeutic strategies targeting SMYD3 and its molecular partners.

Main Methods:

• Utilized a library of rare tripeptides to test in vitro binding affinity to SMYD3.
• Employed in silico analysis to screen the human proteome for potential SMYD3 interactors based on tripeptide screening.
• Clustered identified proteins based on their involvement in cancer hallmarks.

Main Results:

• Identified mTOR, BLM, MET, AMPK, and p130 as novel SMYD3 interactors.
• These newly identified interactors are implicated in various cancer processes.
• The in silico methodology proved effective in identifying potential protein interactors.

Conclusions:

• The study expands the known interactome of SMYD3, revealing new potential roles in cancer.
• The identified SMYD3 interactors offer potential targets for novel cancer therapies.
• The in silico approach can be valuable for discovering interactors of other proteins of interest.